Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-63.81%||Sales Growth - Q/Q||-10.52%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-50.75%||ROE||-203.75%||ROI|
|Current Ratio||2.77||Quick Ratio||Long Term Debt/Equity||Debt Ratio||1.36|
|Gross Margin||Operating Margin||-245.92%||Net Profit Margin||-274.14%||Dividend Payout Ratio|
|Cash From Financing Activities||-730 K||Cash From Investing Activities||-1.31 M||Cash From Operating Activities||-33.06 M||Gross Profit|
|Net Profit||-40.73 M||Operating Profit||-36.75 M||Total Assets||153.15 M||Total Current Assets||143.9 M|
|Total Current Liabilities||51.91 M||Total Debt||Total Liabilities||115 M||Total Revenue||5.81 M|
|High 52 week||23.37||Low 52 week||8.38||Last close||19.15||Last change||-2.84%|
|RSI||61.92||Average true range||1.22||Beta||1.59||Volume||340.72 K|
|Simple moving average 20 days||6%||Simple moving average 50 days||-0.5%||Simple moving average 200 days||29.13%|
|Performance Week||-4.35%||Performance Month||-3.04%||Performance Quart||9.62%||Performance Half||36.01%|
|Performance Year||4.36%||Performance Year-to-date||111.6%||Volatility daily||4.49%||Volatility weekly||10.05%|
|Volatility monthly||20.59%||Volatility yearly||71.32%||Relative Volume||232.26%||Average Volume||1.11 M|
|New High||New Low|
2020-05-26 12:53:42 | Is Coherus BioSciences a Buy?
2020-05-21 12:47:42 | 3 Stocks Trading at Attractive Valuations
2020-05-13 19:08:15 | Coherus Is a ‘Top Pick’ for COVID-19 Environment, Says Top Analyst
2020-05-10 22:47:26 | Were Hedge Funds Right About Coherus Biosciences Inc CHRS?
2020-05-08 19:33:38 | Edited Transcript of CHRS earnings conference call or presentation 7-May-20 8:30pm GMT
2020-05-08 17:30:32 | Coherus BioSciences Inc CHRS Q1 2020 Earnings Call Transcript
2020-05-07 16:08:48 | Coherus BioSciences Reports First Quarter 2020 Financial Results
2020-05-04 09:30:10 | Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference
2020-04-30 12:34:04 | Coherus BioSciences CHRS Earnings Expected to Grow: Should You Buy?
2020-04-22 09:30:10 | Coherus BioSciences to Report First Quarter Financial Results on May 7th
2020-04-16 07:27:11 | Check These 7 Top-Ranked Stocks With Solid Net Profit Margins
2020-04-15 00:05:36 | Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
2020-04-14 07:52:38 | Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering
2020-04-07 06:59:10 | Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners
2020-03-26 08:34:12 | Is Coherus BioSciences CHRS Stock a Solid Choice Right Now?
2020-03-20 09:30:10 | Coherus BioSciences Announces New Employment Inducement Grants
2020-03-13 18:53:40 | Edited Transcript of CHRS earnings conference call or presentation 27-Feb-20 9:30pm GMT
2020-03-05 16:09:45 | Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020
2020-02-27 16:01:10 | Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-26 09:30:10 | Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference
2020-02-24 09:43:02 | Coherus CHRS to Report Q4 Earnings: What's in the Cards?
2020-02-20 11:19:25 | Coherus BioSciences Announces New Employment Inducement Grants
2020-02-11 11:30:04 | Has Coherus BioSciences CHRS Outpaced Other Medical Stocks This Year?
2020-02-07 12:00:05 | Coherus BioSciences CHRS Upgraded to Strong Buy: Here's Why
2020-01-23 11:30:04 | Has Coherus BioSciences CHRS Outpaced Other Medical Stocks This Year?
2020-01-17 08:16:01 | Arena's ARNA Heart Failure Candidate Gets Fast Track Status
2020-01-13 08:30:10 | Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States
2020-01-08 08:53:01 | Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
2020-01-07 11:30:04 | Is Coherus BioSciences CHRS Stock Outpacing Its Medical Peers This Year?
2020-01-07 09:59:02 | Protagonist PTGX Starts Study on PTG-300 for Blood Disorder
2020-01-03 09:55:02 | Pulmatrix Surges on License Agreement With Johnson & Johnson
2020-01-03 09:01:02 | Arena ARNA Expands Strategic Deal With Beacon Discovery
2019-12-30 09:44:02 | Flexion's FLXN Stock Up on FDA Approval for Zilretta sNDA
2019-12-19 11:30:04 | Has Coherus BioSciences CHRS Outpaced Other Medical Stocks This Year?
2019-12-16 08:55:01 | 5 Biotech Stocks Set for Continued Rally in 2020
2019-12-07 12:25:53 | Is Coherus Biosciences Inc CHRS A Good Stock To Buy ?
2019-12-03 08:51:01 | Top Ranked Momentum Stocks to Buy for December 3rd
2019-11-26 11:27:04 | Top Ranked Momentum Stocks to Buy for November 26th
2019-11-19 09:36:02 | Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline